Lower risk of hospitalisation for heart failure, kidney disease and death with sodium glucose co-transporter-2 compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care
Obese sedentary cohorts show partial neutralization of Gs-driven chronotropy by upregulated Gi coupling, producing a fundamentally different Hill curve than the intact-Gs signaling of lean responsive cohorts
Eriksson, J
These medications mimic the natural actions of GLP-1, improving insulin secretion, enhancing glucose management, and promoting weight loss in patients with type 2 diabetes or obesity
Our providers can help you explore both brand-name and compounded medication options, with transparent pricing and a commitment to continuity of care
There is therefore no doubt that semaglutide and tirzepatide represent extremely interesting additions to the pharmacological approach to obesity, especially since these drugs are generally relatively well tolerated
